title: Tumour necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) and soluble TNF-alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.
abstract: OBJECTIVE
  The aim of the study was to examine the tumour necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) concentration in peripheral blood mononuclear cells (PBMC) and its relationship with plasma concentration of soluble TNF-alpha receptor type 1 (sTNF-R1) and with the disease severity in psoriasis patients treated with narrowband ultraviolet B (NB-UVB).
  
  
  METHODS
  The study has been conducted among 40 patients with plaque-type psoriasis vulgaris: 23 had only skin lesions (PV) and 17 had co-existing, inactive, psoriatic arthritis (PsA). Control blood samples were obtained from 20 healthy subjects. The assessment of the severity of skin lesions (using Psoriasis Area and Severity Index - PASI), TACE and sTNF-R1 concentrations (using quantitative sandwich enzyme immunoassays) have been performed at baseline (T 0) and after 20 NB-UVB irradiations (T 20).
  
  
  RESULTS
  The baseline sTNF-R1 and TACE concentrations in all patients was higher than that in controls (2.55 +/- 1.67 vs. 1.70 +/- 0.15 ng/ml, P<0.001, respectively, and 2.62 +/- 0.32 vs. 1.31 +/- 0.30 ng/ml, P<0.001, respectively). The sTNF-R1 and TACE concentrations were lower in PV than in PsA patients (2.47 +/- 0.16 vs. 2.65 +/- 0.13 ng/ml, and 2.52 +/- 0.22 vs. 2.76 +/- 0.39 ng/ml, P<0.05, respectively). The baseline PASI correlated with sTNF-R1 and to TACE concentrations (R=0.48 and 0.39, P<0.05, respectively). The sTNF-R1 correlated to TACE concentration (R=0.52, P<0.05). The significant decline in sTNF-R1 and TACE concentrations at T 20 was noticed, TACE reached control values (1.20 +/- 0.44 ng/ml in PV patients and 1.16 +/- 0.48 ng/ml in PsA patients, respectively).
  
  
  CONCLUSIONS
  TACE from PBMC can contribute to up-regulation of sTNF-R1 in patients with active psoriasis vulgaris and with psoriatic arthritis. It also can serve as a sensitive marker of the disease severity.
authors.affiliation: Department of Dermatology and Venereology, Medical University of Bialystok, Poland. agabser@amb.edu.pl
authors.forename: Agnieszka Beata
authors.initials: AB
authors.lastname: Serwin
authors.forename: Marianna
authors.initials: M
authors.lastname: Sokolowska
authors.forename: Bozena
authors.initials: B
authors.lastname: Chodynicka
mesh_terms: D051722:ADAM Proteins / Q000097:blood*; D000072198:ADAM17 Protein; D000328:Adult; D015535:Arthritis, Psoriatic / Q000097:blood / Q000201:enzymology / Q000532:radiotherapy*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007963:Leukocytes, Mononuclear / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000201:enzymology / Q000532:radiotherapy*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D014467:Ultraviolet Therapy / Q000379:methods
chemical_list: D015415:Biomarkers; D047888:Receptors, Tumor Necrosis Factor, Type I; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human